Chongqing Pharscin Pharmaceutical Co Ltd - Asset Resilience Ratio

Latest as of September 2025: 14.54%

Chongqing Pharscin Pharmaceutical Co Ltd (002907) has an Asset Resilience Ratio of 14.54% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets

CN¥290.43 Million
≈ $42.50 Million USD Cash + Short-term Investments

Total Assets

CN¥2.00 Billion
≈ $292.33 Million USD All company assets

Resilience Assessment

Moderate
Financial Resilience Level

Asset Resilience Ratio Trend (2017–2024)

This chart shows how Chongqing Pharscin Pharmaceutical Co Ltd's Asset Resilience Ratio has changed over time. Check how strategically is Chongqing Pharscin Pharmaceutical Co Ltd's equity deployed to assess the company's strategic physical and investment asset allocation.

Liquid Assets Composition Over Time

This chart breaks down Chongqing Pharscin Pharmaceutical Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 002907 market cap.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents CN¥0.00 0%
Short-term Investments CN¥290.43 Million 14.54%
Total Liquid Assets CN¥290.43 Million 14.54%

Asset Resilience Insights

  • Moderate Liquidity: Chongqing Pharscin Pharmaceutical Co Ltd has 14.54% of assets in liquid form.
  • While adequate for normal operations, this level may limit flexibility during economic stress.
  • The company has significant short-term investments, indicating active treasury management.

Chongqing Pharscin Pharmaceutical Co Ltd Industry Peers by Asset Resilience Ratio

Compare Chongqing Pharscin Pharmaceutical Co Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Takeda Pharmaceutical Company Limited
F:TKDA
Drug Manufacturers - Specialty & Generic 0.69%
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858
Drug Manufacturers - Specialty & Generic 3.47%
Beijing Sun Novo Pharmaceutical Research Co Ltd
SHG:688621
Drug Manufacturers - Specialty & Generic 2.04%
Guizhou Xinbang Pharmaceutical Co Ltd
SHE:002390
Drug Manufacturers - Specialty & Generic 0.01%
Guangdong Lifestrong Pharmacy Co. Ltd.
SHE:301111
Drug Manufacturers - Specialty & Generic 7.85%
Jw Pharmac
KO:001060
Drug Manufacturers - Specialty & Generic 3.65%
Kamada
TA:KMDA
Drug Manufacturers - Specialty & Generic 0.00%
Samjin Pharm
KO:005500
Drug Manufacturers - Specialty & Generic 0.25%

Annual Asset Resilience Ratio for Chongqing Pharscin Pharmaceutical Co Ltd (2017–2024)

The table below shows the annual Asset Resilience Ratio data for Chongqing Pharscin Pharmaceutical Co Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2024-12-31 6.29% CN¥120.61 Million
≈ $17.65 Million
CN¥1.92 Billion
≈ $280.60 Million
+10.63pp
2023-12-31 -4.34% CN¥-80.31 Million
≈ $-11.75 Million
CN¥1.85 Billion
≈ $270.93 Million
-3.32pp
2022-12-31 -1.02% CN¥-18.97 Million
≈ $-2.78 Million
CN¥1.87 Billion
≈ $273.15 Million
-5.57pp
2021-12-31 4.55% CN¥80.61 Million
≈ $11.80 Million
CN¥1.77 Billion
≈ $259.22 Million
+1.64pp
2020-12-31 2.91% CN¥50.07 Million
≈ $7.33 Million
CN¥1.72 Billion
≈ $251.90 Million
-8.89pp
2019-12-31 11.80% CN¥193.25 Million
≈ $28.28 Million
CN¥1.64 Billion
≈ $239.61 Million
-8.08pp
2017-12-31 19.88% CN¥176.00 Million
≈ $25.75 Million
CN¥885.15 Million
≈ $129.52 Million
--
pp = percentage points

About Chongqing Pharscin Pharmaceutical Co Ltd

SHE:002907 China Drug Manufacturers - Specialty & Generic
Market Cap
$787.68 Million
CN¥5.38 Billion CNY
Market Cap Rank
#9859 Global
#2526 in China
Share Price
CN¥12.89
Change (1 day)
+1.02%
52-Week Range
CN¥11.69 - CN¥19.08
All Time High
CN¥42.89
About

Chongqing Pharscin Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of drugs in China. The company offers tablets, powders, granules, soft capsules, powder injections, freeze-dried powders, injections, chemical raw materials, and small volume injections. It provides its products for the treatment of CNS, digestion, otolaryngology, oncology, cardiovascular, an… Read more